Legal Representation
Attorney
Mark D. Godler
USPTO Deadlines
Application History
16 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 7, 2014 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Oct 9, 2013 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| Oct 9, 2013 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Mar 4, 2013 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 4, 2013 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 4, 2013 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 1, 2013 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 28, 2013 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 28, 2013 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Sep 5, 2012 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Sep 5, 2012 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Sep 5, 2012 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Sep 5, 2012 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 22, 2012 | MPMK | O | NOTICE OF PSEUDO MARK MAILED | Loading... |
| May 18, 2012 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 17, 2012 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Medicinal and biological preparations for research, laboratory use, pharmaceutical, clinical or medical laboratory use, namely, preparations for the modulation of gene and protein expression working at DNA transcription, RNA translation and/or degradation processes related thereto
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
MicroRNA-targeted pharmaceutical drug research and development in the field of biotech herapeutics; development of RNA-based pharmaceutical drugs and therapeutic compounds; development of drugs for the pharmaceutical and biotech industries for the treatment of a wide variety of diseases and other conditions, namely, cardiovascular diseases, endocrine and metabolic diseases, obesity and weight disorders, hepatic and gastro-intestinal diseases, inflammatory diseases, and malignant diseases; Scientific and technological research services, namely, profiling and analysis of miRNA sequences; developing computer generated models and simulations for others; providing "in vitro" and "in vivo" preclinical and clinical testing of microRNA analogs and aptamers for scientific, research, healthcare, product development, consulting, and educational purposes
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Translation
The wording AptamiR has no meaning in a foreign language.
Pseudo Mark
APTAMI R
Classification
International Classes
005
042